A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumorsYasuki Hijikata, Kenzaburo Tani, Yuichi Yamada et al.|PLoS ONE|2018Cited by 17